Veeva Systems
Indexed for the AI capabilities inside the Veeva Vault platform rather than for the platform itself, which is context under this index's product scoping rule. Veeva (NYSE: VEEV) is the dominant software platform for life sciences, spanning clinical, regulatory, safety, quality, medical, and commercial, with customers including Novo Nordisk, Gilead, Bristol Myers Squibb, Merck, Roche, Moderna, and BioMarin. Veeva AI Agents became available in December 2025, initially for Vault CRM (Free Text Agent flagging issues in call notes, Voice Agent for spoken input, Pre-call Agent assembling context) and PromoMats (Quick Check Agent scanning promotional content against brand and regulatory guidelines before medical, legal, and regulatory review, and Content Agent assisting reviewers). Agents are built on large language models from providers including Anthropic and Amazon, hosted on Amazon Bedrock but operating inside the Vault environment, accessible through the Vault interface or API and customizable through Veeva's AI framework. Safety and quality agents are reported live, with clinical and regulatory agents tied to the 26R2 release. Availability matters here and is stated rather than blurred: two further announced product lines are not yet available. Falcon, a separate platform for standardized agentic labor covering trial master file intake, safety case processing, and health authority interaction management, targets late 2026 for early adopters, and Agentic Authoring, which drafts submissible regulatory documents, is expected in late 2027. Neither is indexed as a shipping capability.
Capability Axes
The fourth product scoped platform vendor in this index, and the grade is descriptive. What a life sciences company buys is Vault, the system of record across clinical, regulatory, safety, quality, and commercial. The AI agents are additions to that platform, shipping from December 2025 onward, and the company's framing of agents working seamlessly inside Veeva applications places them correctly as a layer. No customer selects Veeva for the agents.
The clearest model provenance disclosure among the platform vendors indexed here. The company states its agents are built on large language models from named providers including Anthropic and Amazon, hosted on Amazon Bedrock, while operating inside the Vault environment so customer data stays within the platform boundary. Naming the underlying model providers and the hosting arrangement is materially more useful than an unattributed reference to proprietary AI, and it lets a buyer reason about model risk and data residency directly. Agents are also accessible by API and customizable through a published framework rather than being closed.
Platform adoption is exceptional and includes most of the largest pharmaceutical companies, but that is evidence for Vault rather than for the agents, and the agents are recent. Customer commentary is early and appropriately hedged, with one named customer describing the promotional content agent as moving them closer to a process where parts of medical, legal, and regulatory review could become automated, which is a statement of direction rather than a measured result. A vendor projection of 15 to 20 percent industry efficiency improvement is a forecast, not evidence.
No public pricing. Contact the vendor. Enterprise agreements with life sciences companies. As with other platform vendors indexed under the scope rule, establish whether agents carry incremental cost or are included in Vault licensing. Note also that two significant announced capabilities, Falcon and Agentic Authoring, are not yet available and target late 2026 and late 2027 respectively; this index does not treat announced roadmap as shipping capability, and buyers should not price against it.
Announced breadth spans clinical, regulatory, safety, quality, medical, and commercial, but shipped coverage is narrower and the distinction is what matters. As of the December 2025 launch the available agents were commercial: CRM call notes, voice capture, pre call preparation, and promotional content review ahead of medical, legal, and regulatory sign off. Safety and quality agents are reported live, with clinical and regulatory tied to a later release. Buyers should evaluate against what is generally available for their function rather than the roadmap.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Contact the vendor
|
Enterprise Vault agreements scoped by application and users | — | — | Vendor Published |
No rate card published. Enterprise agreements with life sciences companies, typically scoped by application and user count across the Vault suite. Two things to settle in procurement: whether AI agents carry incremental cost or are included in existing Vault licensing, and what is actually contractable today. Falcon and Agentic Authoring are announced but not available, targeting late 2026 for early adopters and late 2027 respectively, and should not be priced or planned against as current capability.